Wang Yaning, Chen Wanqi, Shi Yixin, Yan Chengrui, Kong Ziren, Wang Yuekun, Wang Yu, Ma Wenbin
Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Department of Neurosurgery, Peking University International Hospital, Beijing, China.
Front Oncol. 2021 Sep 9;11:719623. doi: 10.3389/fonc.2021.719623. eCollection 2021.
The most common primary intracranial tumor is glioma, among which glioblastoma (GBM) has the worst prognosis. Because of the high degree of malignancy of GBM and frequent recurrence after surgery, postoperative therapy, including chemotherapy, radiotherapy, targeted therapy, and immunotherapy, is particularly important. A wide variety of targeted drugs have undergone phase III clinical trials for patients with GBM, but these drugs do not work for all patients, and few patients in these trials have prolonged overall survival. In this review, some imposing phase III clinical trials of targeted drugs for glioma are introduced, and some prospective phase II clinical trials that have been completed or are in progress are summarized. In addition, the mechanisms of these drugs are briefly introduced, and deficiencies of these clinical trials are analyzed. This review aims to provide a comprehensive overview of current research on targeted drugs for glioma to clarify future research directions.
最常见的原发性颅内肿瘤是胶质瘤，其中胶质母细胞瘤（GBM）的预后最差。由于GBM的高度恶性以及手术后频繁复发，包括化疗、放疗、靶向治疗和免疫治疗在内的术后治疗尤为重要。多种靶向药物已针对GBM患者进行了III期临床试验，但这些药物并非对所有患者都有效，而且这些试验中很少有患者的总生存期得到延长。在本综述中，介绍了一些针对胶质瘤的靶向药物的重要III期临床试验，并总结了一些已经完成或正在进行的前瞻性II期临床试验。此外，简要介绍了这些药物的作用机制，并分析了这些临床试验的不足之处。本综述旨在全面概述目前关于胶质瘤靶向药物的研究，以明确未来的研究方向。
